Thrivent Financial for Lutherans Takes Position in Blueprint Medicines Corp (NASDAQ:BPMC)

Thrivent Financial for Lutherans acquired a new stake in Blueprint Medicines Corp (NASDAQ:BPMC) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,903 shares of the biotechnology company’s stock, valued at approximately $345,000.

A number of other large investors have also recently added to or reduced their stakes in BPMC. Rothschild & Co. Asset Management US Inc. boosted its stake in shares of Blueprint Medicines by 7.5% during the 1st quarter. Rothschild & Co. Asset Management US Inc. now owns 103,921 shares of the biotechnology company’s stock worth $6,077,000 after acquiring an additional 7,213 shares in the last quarter. Eaton Vance Management increased its stake in Blueprint Medicines by 137.9% in the 1st quarter. Eaton Vance Management now owns 512,297 shares of the biotechnology company’s stock worth $29,959,000 after purchasing an additional 296,931 shares in the last quarter. Geode Capital Management LLC lifted its stake in Blueprint Medicines by 14.8% during the first quarter. Geode Capital Management LLC now owns 793,609 shares of the biotechnology company’s stock valued at $46,409,000 after buying an additional 102,291 shares in the last quarter. Tekla Capital Management LLC lifted its stake in Blueprint Medicines by 19.2% during the first quarter. Tekla Capital Management LLC now owns 139,336 shares of the biotechnology company’s stock valued at $8,148,000 after buying an additional 22,411 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Blueprint Medicines by 7.7% in the first quarter. Legal & General Group Plc now owns 35,447 shares of the biotechnology company’s stock worth $2,073,000 after buying an additional 2,545 shares during the period. 97.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BPMC stock opened at $76.55 on Wednesday. Blueprint Medicines Corp has a 12 month low of $43.29 and a 12 month high of $102.98. The company has a market cap of $4.15 billion, a PE ratio of -10.30 and a beta of 1.09. The company has a quick ratio of 7.14, a current ratio of 7.17 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $70.11 and its two-hundred day moving average is $67.50.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.08) by ($0.03). The firm had revenue of $6.20 million during the quarter, compared to analyst estimates of $5.57 million. Blueprint Medicines had a negative net margin of 515.98% and a negative return on equity of 65.81%. The business’s quarterly revenue was up 749.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.98) earnings per share. As a group, equities analysts expect that Blueprint Medicines Corp will post -8.4 EPS for the current fiscal year.

BPMC has been the subject of a number of recent analyst reports. SVB Leerink decreased their price objective on shares of Blueprint Medicines from $125.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, April 29th. BidaskClub lowered Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Blueprint Medicines in a report on Thursday, May 7th. Canaccord Genuity reduced their price target on shares of Blueprint Medicines from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Finally, JMP Securities lowered their price objective on shares of Blueprint Medicines from $107.00 to $103.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Blueprint Medicines has a consensus rating of “Buy” and an average target price of $93.54.

In other news, insider Debra Durso-Bumpus sold 2,500 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $75.18, for a total value of $187,950.00. Following the sale, the insider now owns 22,005 shares in the company, valued at $1,654,335.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ariel Hurley sold 700 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $75.00, for a total transaction of $52,500.00. Following the transaction, the insider now directly owns 10,684 shares in the company, valued at approximately $801,300. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,217 shares of company stock worth $2,578,985. 3.81% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: Retained Earnings

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.